Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan and Ivonescimab in HER2-Altered Advanced NSCLC
NCT07630077Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07630077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07630077.